Literature DB >> 22081778

No acquisition: a new ambition for HIV vaccine development?

Samir K Lakhashe1, Guido Silvestri, Ruth M Ruprecht.   

Abstract

Development of a safe and effective prophylactic HIV-1 vaccine presents unique challenges. The pessimism following the failure of two HIV-1 vaccine concepts in clinical trials, HIV-1 gp120 and an adenovirus-based approach to induce only cellular immune responses, has been replaced by cautious optimism engendered by the RV144 trial outcome, the isolation of several new broadly reactive neutralizing monoclonal antibodies, and recent primate model data indicating prevention of viral acquisition by active or passive immunization. Intense efforts are underway to optimize immunogen design, adjuvants, and the tools for preclinical evaluation of candidate vaccines in primates, where correlates of protection can be examined in detail - as proof-of-concept for clinical trials.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22081778      PMCID： PMC3210480          DOI： 10.1016/j.coviro.2011.07.005

Source DB:  PubMed          Journal:  Curr Opin Virol        ISSN： 1879-6257            Impact factor:   7.090


  75 in total

1.  DNA vaccination in rhesus macaques induces potent immune responses and decreases acute and chronic viremia after SIVmac251 challenge.

Authors:  Margherita Rosati; Cristina Bergamaschi; Antonio Valentin; Viraj Kulkarni; Rashmi Jalah; Candido Alicea; Vainav Patel; Agneta S von Gegerfelt; David C Montefiori; David J Venzon; Amir S Khan; Ruxandra Draghia-Akli; Koen K A Van Rompay; Barbara K Felber; George N Pavlakis
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-28       Impact factor: 11.205

2.  Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge.

Authors:  Scott G Hansen; Cassandra Vieville; Nathan Whizin; Lia Coyne-Johnson; Don C Siess; Derek D Drummond; Alfred W Legasse; Michael K Axthelm; Kelli Oswald; Charles M Trubey; Michael Piatak; Jeffrey D Lifson; Jay A Nelson; Michael A Jarvis; Louis J Picker
Journal:  Nat Med       Date:  2009-02-15       Impact factor: 53.440

3.  Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals.

Authors:  Johannes F Scheid; Hugo Mouquet; Niklas Feldhahn; Michael S Seaman; Klara Velinzon; John Pietzsch; Rene G Ott; Robert M Anthony; Henry Zebroski; Arlene Hurley; Adhuna Phogat; Bimal Chakrabarti; Yuxing Li; Mark Connors; Florencia Pereyra; Bruce D Walker; Hedda Wardemann; David Ho; Richard T Wyatt; John R Mascola; Jeffrey V Ravetch; Michel C Nussenzweig
Journal:  Nature       Date:  2009-03-15       Impact factor: 49.962

4.  Vaccine-induced cellular responses control simian immunodeficiency virus replication after heterologous challenge.

Authors:  Nancy A Wilson; Brandon F Keele; Jason S Reed; Shari M Piaskowski; Caitlin E MacNair; Andrew J Bett; Xiaoping Liang; Fubao Wang; Elizabeth Thoryk; Gwendolyn J Heidecker; Michael P Citron; Lingyi Huang; Jing Lin; Salvatore Vitelli; Chanook D Ahn; Masahiko Kaizu; Nicholas J Maness; Matthew R Reynolds; Thomas C Friedrich; John T Loffredo; Eva G Rakasz; Stephen Erickson; David B Allison; Michael Piatak; Jeffrey D Lifson; John W Shiver; Danilo R Casimiro; George M Shaw; Beatrice H Hahn; David I Watkins
Journal:  J Virol       Date:  2009-04-29       Impact factor: 5.103

5.  Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans.

Authors:  David I Watkins; Dennis R Burton; Esper G Kallas; John P Moore; Wayne C Koff
Journal:  Nat Med       Date:  2008-06       Impact factor: 53.440

6.  Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial.

Authors:  Susan P Buchbinder; Devan V Mehrotra; Ann Duerr; Daniel W Fitzgerald; Robin Mogg; David Li; Peter B Gilbert; Javier R Lama; Michael Marmor; Carlos Del Rio; M Juliana McElrath; Danilo R Casimiro; Keith M Gottesdiener; Jeffrey A Chodakewitz; Lawrence Corey; Michael N Robertson
Journal:  Lancet       Date:  2008-11-13       Impact factor: 79.321

7.  Neutralization-sensitive R5-tropic simian-human immunodeficiency virus SHIV-2873Nip, which carries env isolated from an infant with a recent HIV clade C infection.

Authors:  Nagadenahalli B Siddappa; Ruijiang Song; Victor G Kramer; Agnès-Laurence Chenine; Vijayakumar Velu; Helena Ong; Robert A Rasmussen; Ricky D Grisson; Charles Wood; Hong Zhang; Chipeppo Kankasa; Rama Rao Amara; James G Else; Francis J Novembre; David C Montefiori; Ruth M Ruprecht
Journal:  J Virol       Date:  2008-11-19       Impact factor: 5.103

Review 8.  Elite control of HIV infection: implications for vaccine design.

Authors:  B M Baker; B L Block; A C Rothchild; B D Walker
Journal:  Expert Opin Biol Ther       Date:  2009-01       Impact factor: 4.388

9.  Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys.

Authors:  Jinyan Liu; Kara L O'Brien; Diana M Lynch; Nathaniel L Simmons; Annalena La Porte; Ambryice M Riggs; Peter Abbink; Rory T Coffey; Lauren E Grandpre; Michael S Seaman; Gary Landucci; Donald N Forthal; David C Montefiori; Angela Carville; Keith G Mansfield; Menzo J Havenga; Maria G Pau; Jaap Goudsmit; Dan H Barouch
Journal:  Nature       Date:  2008-11-09       Impact factor: 49.962

10.  Acute Schistosoma mansoni infection increases susceptibility to systemic SHIV clade C infection in rhesus macaques after mucosal virus exposure.

Authors:  Agnès-Laurence Chenine; Ela Shai-Kobiler; Lisa N Steele; Helena Ong; Peter Augostini; Ruijiang Song; Sandra J Lee; Patrick Autissier; Ruth M Ruprecht; W Evan Secor
Journal:  PLoS Negl Trop Dis       Date:  2008-07-23
View more
  12 in total

1.  Controversies in HIV cure research.

Authors:  Rowena Johnston; Françoise Barré-Sinoussi
Journal:  J Int AIDS Soc       Date:  2012-03-16       Impact factor: 5.396

2.  Adaptation of an R5 Simian-Human Immunodeficiency Virus Encoding an HIV Clade A Envelope with or without Ablation of Adaptive Host Immunity: Differential Selection of Viral Mutants.

Authors:  Mingkui Zhou; Michael Humbert; Muhammad M Mukhtar; Hanna B Scinto; Hemant K Vyas; Samir K Lakhashe; Siddappa N Byrareddy; Gregor Maurer; Swati Thorat; Joshua Owuor; Zhao Lai; Yidong Chen; Anthony Griffiths; Agnès-Laurence Chenine; Sanjeev Gumber; François Villinger; David Montefiori; Ruth M Ruprecht
Journal:  J Virol       Date:  2019-04-17       Impact factor: 5.103

3.  High-level, lasting antiviral immunity induced by a bimodal AIDS vaccine and boosted by live-virus exposure: prevention of viremia.

Authors:  Robert A Rasmussen; Nagadenahalli B Siddappa; Samir K Lakhashe; Jennifer Watkins; François Villinger; Chris Ibegbu; Ruth H Florese; Marjorie Robert-Guroff; David C Montefiori; Donald N Forthal; David O'Connor; Ruth M Ruprecht
Journal:  AIDS       Date:  2012-01-14       Impact factor: 4.177

4.  Humoral immunity induced by mucosal and/or systemic SIV-specific vaccine platforms suggests novel combinatorial approaches for enhancing responses.

Authors:  Diego A Vargas-Inchaustegui; Iskra Tuero; Venkatramanan Mohanram; Thomas Musich; Poonam Pegu; Antonio Valentin; Yongjun Sui; Margherita Rosati; Jenifer Bear; David J Venzon; Viraj Kulkarni; Candido Alicea; Guy R Pilkington; Namal P M Liyanage; Thorsten Demberg; Shari N Gordon; Yichuan Wang; Alison E Hogg; Blake Frey; L Jean Patterson; Janet DiPasquale; David C Montefiori; Niranjan Y Sardesai; Steven G Reed; Jay A Berzofsky; Genoveffa Franchini; Barbara K Felber; George N Pavlakis; Marjorie Robert-Guroff
Journal:  Clin Immunol       Date:  2014-06-04       Impact factor: 3.969

5.  Novel biopanning strategy to identify epitopes associated with vaccine protection.

Authors:  Barbara C Bachler; Michael Humbert; Brisa Palikuqi; Nagadenahalli B Siddappa; Samir K Lakhashe; Robert A Rasmussen; Ruth M Ruprecht
Journal:  J Virol       Date:  2013-02-06       Impact factor: 5.103

6.  Multimodality vaccination against clade C SHIV: partial protection against mucosal challenges with a heterologous tier 2 virus.

Authors:  Samir K Lakhashe; Siddappa N Byrareddy; Mingkui Zhou; Barbara C Bachler; Girish Hemashettar; Shiu-Lok Hu; Francois Villinger; James G Else; Shannon Stock; Sandra J Lee; Diego A Vargas-Inchaustegui; Egidio Brocca Cofano; Marjorie Robert-Guroff; Welkin E Johnson; Victoria R Polonis; Donald N Forthal; Erwann P Loret; Robert A Rasmussen; Ruth M Ruprecht
Journal:  Vaccine       Date:  2014-09-20       Impact factor: 3.641

7.  Generation and characterization of a defective HIV-1 Virus as an immunogen for a therapeutic vaccine.

Authors:  Carmen Álvarez-Fernández; Alberto Crespo Guardo; Javier García-Pérez; Felipe García; Julia Blanco; Laura Escribà-García; Jose Maria Gatell; Jose Alcamí; Montserrat Plana; Sonsoles Sánchez-Palomino
Journal:  PLoS One       Date:  2012-11-07       Impact factor: 3.240

8.  Interplay between HIV-1 and Host Genetic Variation: A Snapshot into Its Impact on AIDS and Therapy Response.

Authors:  Raghavan Sampathkumar; Elnaz Shadabi; Ma Luo
Journal:  Adv Virol       Date:  2012-05-16

9.  Live-virus exposure of vaccine-protected macaques alters the anti-HIV-1 antibody repertoire in the absence of viremia.

Authors:  Barbara C Bachler; Michael Humbert; Samir K Lakhashe; Robert A Rasmussen; Ruth M Ruprecht
Journal:  Retrovirology       Date:  2013-06-21       Impact factor: 4.602

10.  Synthetic immunotherapy induces HIV virus specific Th1 cytotoxic response and death of an HIV-1 infected human cell line through classic complement activation.

Authors:  Olga Pleguezuelos; Gregory A Stoloff; Wilson Caparrós-Wanderley
Journal:  Virol J       Date:  2013-04-04       Impact factor: 4.099
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.